Ariad Pharmaceuticals Inc fka ARIA

[gr8db8]

What do you think? Just saw this on stocktwit. Looks very promising for Ponatinib. Good, no?

Comparative Efficacy of Tyrosine Kinase Inhibitor Treatments in the Third-Line Setting, for Chronic-Phase Chronic Myelogenous Leukemia after Failure of Second-Generation Tyrosine Kinase Inhibitors
J.H. Liptona, P. Brydenb, M.K. Sidhuc, , , H. Huangd, L.J. McGarryd, S. Lustgartend, S. Mealingb, B. Woodsb, J. Whelanb, N. Hawkinsb
a Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada
b CON Health Economics; Oxford, UK
c CON Health Economics; Morristown, NJ, USA
d ARIAD Pharmaceuticals, Inc.; Cambridge MA, USA
Received 12 May 2014, Revised 15 October 2014, Accepted 24 October 2014, Available online 1 November 2014

Highlights
•
We compared the efficacy of ponatinib and 2G-TKIs in CP-CML after =1 prior 2G-TKI.
•
Relevant studies were identified by systematic review.
•
Estimated response to 2G-TKI was 22-26% vs 60% (95%CrI 52-68%) with ponatinib.
•
Probability of response was greater with ponatinib than with a further 2G-TKI.

Abstract
We compared the efficacy of ponatinib and second-generation tyrosine kinase inhibitors (2G-TKIs: bosutinib, dasatinib, and nilotinib) in chronic phase CML resistant/intolerant to =1 prior 2G-TKI. Estimated probabilities of CCyR with 2G-TKI ranged from 22% to 26%, compared with 60% (95% CrI 52-68%) with ponatinib. The estimated probability of ponatinib providing higher response rate than all other included treatments was 99% (CCyR) and 97% (MCyR). Use of further 2G-TKI may provide limited benefit in CP-CML patients resistant/intolerant to prior 2G-TKI treatment. Compared with 2G-TKIs, ponatinib is estimated to provide substantially higher probability of achieving CCyR and MCyR; safety was not compared.

http://www.sciencedirect.com/science/article/pii/S0145212614003270